Search results for SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[BasicSearch] Leiomyosarcoma - ICH GCP

Clinical Trials: SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[BasicSearch] Leiomyosarcoma

NCTID/Status

Study

Last Changed

NCT03437070
Withdrawn

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Conditions: Leiomyosarcoma
Intervention: Trabectedin, Doxorubicin, Olaratumab

March 14, 2019

NCT02249702
Completed

Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
Conditions: Leiomyosarcoma
Intervention: Gemcitabine + Docetaxel, Trabectedin

December 5, 2017

NCT01442662
Unknown status

Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
Conditions: Leiomyosarcoma
Intervention: Pazopanib + Gemcitabine

March 19, 2015

NCT03536780
Recruiting

Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
Conditions: Leiomyosarcoma Metastatic
Intervention: Avelumab And Gemcitabine

February 13, 2019

NCT02247544
Completed

Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Conditions: Liposarcoma; Leiomyosarcoma
Intervention: Trabectedin

May 9, 2019

NCT02378142
Withdrawn

Pazopanib for Treating Uterine Leiomyosarcoma
Conditions: Uterine Leiomyosarcoma
Intervention: Pazopanib

November 17, 2015

NCT02131480
Completed

Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma
Conditions: Uterus Leiomyosarcoma; Soft Tissue Leiomyosarcoma
Intervention: Doxorubicin, Trabectedin

January 25, 2017

NCT02997358
Not yet recruiting

Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma
Conditions: Uterine or Soft Tissue Leiomyosarcoma
Intervention: Doxorubicin, Trabectedin

January 6, 2017

NCT00614835
Completed

Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Conditions: Uterine Leiomyosarcoma; Uterine Cancer
Intervention: Docetaxel Plus Gemcitabine

December 21, 2015

NCT01692678
Completed

A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Conditions: Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Intervention: Trabectedin, Dacarbazine

July 9, 2018

NCT01343277
Completed

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Conditions: Advanced Liposarcoma or Leiomyosarcoma
Intervention: Trabectedin, Dacarbazine

July 15, 2016

NCT00856050
Completed

Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Conditions: Leiomyosarcoma
Intervention: Letrozole

March 22, 2017

NCT03761095
Recruiting

A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
Conditions: Leiomyosarcoma
Intervention: PTC596, Dacarbazine

November 27, 2019

NCT02428192
Completed

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Conditions: Metastatic Leiomyosarcoma; Unresectable Leiomyosarcoma; Uterine Corpus Leiomyosarcoma
Intervention: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab

September 24, 2018

NCT01637961
Completed

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions: Recurrent Uterine Corpus Sarcoma; Uterine Corpus Leiomyosarcoma
Intervention: Alisertib, Laboratory Biomarker Analysis

July 22, 2019

NCT00282087
Completed

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Conditions: Leiomyosarcoma; Uterine Neoplasm
Intervention: Gemcitabine, Docetaxel, Doxorubicin

November 23, 2014

NCT01426633
Completed

Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Conditions: Leiomyosarcoma; Liposarcoma
Intervention: Gemcitabine + Trabectedin

December 15, 2014

NCT02587169
Unknown status

Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum
Conditions: Retroperitoneal Liposarcoma; Retroperitoneal Leiomyosarcoma; Chondrosarcoma
Intervention: Nilotinib-adriamycin

October 23, 2015

NCT01533207
Unknown status

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma AJCC v7; Uterine Corpus Leiomyosarcoma
Intervention: Clinical Observation, Docetaxel, Doxorubicin Hydrochloride, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim

August 23, 2017

NCT00414076
Terminated

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
Conditions: Leiomyosarcoma; Uterine Neoplasm
Intervention: Letrozole

October 23, 2018

NCT03880019
Recruiting

Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma
Conditions: Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
Intervention: Olaparib, Temozolomide

December 9, 2019

NCT01220609
Completed

Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
Conditions: Recurrent Uterine Corpus Sarcoma; Uterine Corpus Leiomyosarcoma
Intervention: Ixabepilone, Laboratory Biomarker Analysis

August 6, 2019

NCT03074318
Recruiting

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Conditions: Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Liposarcoma
Intervention: Avelumab, Trabectedin

July 12, 2019

NCT02203760
Recruiting

Pazopanib vs. Pazopanib Plus Gemcitabine
Conditions: Leiomyosarcoma or Carcinosarcoma
Intervention: Pazopanib Plus Gemcitabine, Pazopanib

July 8, 2019

NCT00378911
Completed

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions: Recurrent Uterine Sarcoma; Uterine Leiomyosarcoma
Intervention: Sunitinib Malate

July 22, 2019

NCT03114527
Recruiting

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Conditions: Soft Tissue Sarcoma
Intervention: Ribociclib, Everolimus

March 27, 2019

NCT02303262
Completed

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Conditions: Metastatic Leiomyosarcoma
Intervention: Mocetinostat, Gemcitabine

January 4, 2019

NCT03016819
Recruiting

A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Conditions: Alveolar Soft Part Sarcoma; Leiomyosarcoma; Synovial Sarcoma; Soft-Tissue Sarcoma
Intervention: AL 3818, Dacarbazine

September 20, 2019

NCT03810976
Recruiting

A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Conditions: Sarcoma
Intervention: Eribulin, Gemcitabine

January 17, 2019

NCT03773510
Withdrawn

Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
Conditions: Leiomyosarcoma; Liposarcoma; Synovial Sarcoma
Intervention: Trabectedin Discontinuation, Trabectedin Continuation

May 9, 2019

NCT00379145
Completed

Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Conditions: Sarcoma
Intervention: Trabectedin

November 10, 2017

NCT01012297
Terminated

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Conditions: Recurrent Uterine Corpus Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma
Intervention: Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo

July 19, 2019

NCT00310518
Completed

Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
Conditions: Cancer
Intervention: ARQ 501

April 28, 2009

NCT00101127
Completed

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
Conditions: Sarcoma
Intervention: Filgrastim, Pegfilgrastim, Docetaxel, Gemcitabine Hydrochloride

February 12, 2014

NCT00227669
Completed

Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
Conditions: Sarcoma
Intervention: Docetaxel, Gemcitabine Hydrochloride

August 29, 2016

NCT03123276
Recruiting

Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Conditions: Sarcoma
Intervention: Pembrolizumab, Gemcitabine

September 16, 2019

NCT00033709
Unknown status

Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
Conditions: Sarcoma
Intervention: Temozolomide, Thalidomide

January 3, 2014

NCT00004066
Completed

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Conditions: Ovarian Cancer; Sarcoma; Small Intestine Cancer
Intervention: Filgrastim, Docetaxel, Gemcitabine Hydrochloride

March 6, 2013

NCT00060944
Completed

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Conditions: Liposarcoma; Leiomyosarcoma
Intervention: Yondelis, Yondelis, Dexamethasone, Dexamethasone

August 28, 2014

NCT03526679
Recruiting

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
Conditions: Leiomyosarcoma; Liposarcoma; Soft Tissue Sarcoma Adult; Advanced Cancer
Intervention: Eribulin, Lenvatinib

March 12, 2019

NCT00025220
Completed

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Conditions: Recurrent Uterine Corpus Sarcoma; Uterine Corpus Leiomyosarcoma
Intervention: Thalidomide, Laboratory Biomarker Analysis

July 22, 2019

NCT00031629
Completed

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Conditions: Recurrent Uterine Corpus Sarcoma; Uterine Corpus Leiomyosarcoma
Intervention: Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim

December 7, 2016

NCT00003316
Terminated

Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
Conditions: Sarcoma
Intervention: Gemcitabine Hydrochloride

April 10, 2013

NCT00003054
Terminated

Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Conditions: Sarcoma
Intervention: Paclitaxel

April 11, 2018

NCT00033644
Terminated

Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
Conditions: Sarcoma
Intervention: Sargramostim, Cisplatin, Dacarbazine, Doxorubicin Hydrochloride, Mitomycin C

April 10, 2013

NCT03899805
Recruiting

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Conditions: Sarcoma; Liposarcoma; Leiomyosarcoma; Undifferentiated Pleomorphic Sarcoma
Intervention: Eribulin, Pembrolizumab

June 5, 2019

NCT03718091
Recruiting

M6620 (VX-970) in Selected Solid Tumors
Conditions: Solid Tumor; Leiomyosarcoma; Osteosarcoma
Intervention: M6620

November 27, 2019

NCT03851614
Recruiting

Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
Conditions: Mismatch Repair Proficient Colorectal Cancer; Pancreatic Adenocarcinoma; Leiomyosarcoma
Intervention: Durvalumab, Olaparib, Cediranib

May 20, 2019

NCT01958580
Unknown status

Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
Conditions: Stage IA Uterine Sarcoma; Stage IB Uterine Sarcoma; Stage IC Uterine Sarcoma; Stage IIA Uterine Sarcoma; Stage IIB Uterine Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma
Intervention: Gemcitabine Hydrochloride, Docetaxel, Internal Radiation Therapy, Intensity-Modulated Radiation Therapy, External Beam Radiation Therapy, Laboratory Biomarker Analysis

January 16, 2015

NCT04031677
Not yet recruiting

Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Conditions: Retroperitoneal Sarcoma; Liposarcoma; Leiomyosarcoma
Intervention: Surgery, Preoperative Chemotherapy

July 25, 2019

1 2 3 4 Next Last

Last Updated

The last updated date is the most recent date when changes to a clinical trial were submitted to ClinicalTrials.gov. There is often a delay of a few days before the updated trial is available on the clinical trials website.

Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.

Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.

First Received

The first received date is the date when the clinical trial was first submitted to ClinicalTrials.gov. There is often a delay of a few days before the trial is available on the clinical trials website.

Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.

Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.

Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.

Safety Issue

If selected, restricts search results to those studies which have an outcome measure designated as a safety issue. Note that this is a poor estimate of the safety of a treatment or intervention, but it is all we have now.

Funded By

Studies are supported by one or more organizations called sponsors. Support includes contributions of facilities, expertise, and/or financial resources. All sponsors in the database have been assigned one of the following organization types:

National Institutes of Health (NIH)

Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.

Industry - the pharmaceutical companies

University/Organization - all others, including community-based organizations

Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.

Study Phase

Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions that study is seeking to answer:

In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.

In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.

These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.

Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.

Age Group

Studies may be designed for participants of particular ages:

Children (birth-17 yrs old)

Adults (18-65 yrs old)

Senior (66+ yrs old)

Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.

Gender

Searches can be restricted to studies which accept female or male participants.

Location Terms

If you are interested in a specific city (such as Los Angeles) or facility name (such as the Mayo Clinic), enter it as a location term. Not all studies include this level of detail, but if they do, this will find them.

Countries and States

Trials are often conducted at many locations around the world. Select up to three locations to find trials conducted in specific countries. Some countries (currently limited to the United States, Canada, and Australia), locations can be narrowed further by selecting a state.

Study IDs

Each trial is assigned one or more identification numbers by the institute, agency, or organization sponsoring the trial. In addition, clinical trials assigns a unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit. Use this box to search for a trial by NCT identifier or any other study identification numbers.

Examples:

NCT00001789
97-h-0197
ia0006
actg 076

Sponsor (Lead)

Use this box to specify the name of an institute, organization, or company that is conducting a trial.

It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.

A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.

When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.

Examples:

National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb

Sponsor/Collaborators

Use this box to specify institutes, organizations, or companies that are conducting or otherwise supporting a trial.

It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.

Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.

When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.

Examples:

National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb

Outcome Measures

Outcome measures are used to evaluate trial results. For example, an obesity treatment might be evaluated by a measure of weight loss after 6 months. Measures can also be used to quantify side effects, such as number of myocardial infarctions, number of patients with heart arrhythmia, number of suicides, etc.

Use this box to specify an outcome measure used to evaluate trial results.

Examples:

weight loss
heart failure
suicide

Interventions

Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied. Interventions can also include less intrusive possibilities such as surveys, education, and interviews.

Use this box to specify drugs, devices, procedures, or vaccines used in a trial.

Examples:

clofibrate
cyclosporine
vitamin e

Conditions

Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov, conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.

Use this box to specify the conditions being studied.

Examples:

lupus
heart attack
leukemia
risk factors for breast cancer

Study Type

There are three types of studies available in ClinicalTrials.gov:

Interventional:

Studies where individuals are assigned to receive specific interventions. Participants may receive diagnostic, therapeutic or other types of interventions. Assignment of the intervention may or may not be random. Individuals are tracked and biomedical and/or health outcomes are assessed.

Observational:

Studies without an intervention. Studies where biomedical and/or health outcomes are assessed in a pre-defined group of individuals. Participants may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the participants of the study.

Expanded Access:

Records describing the procedure for obtaining an experimental drug or device for patients who are failing on currently available treatments for their condition and also are unable to participate in ongoing clinical trials. Expanded Access records are used to register all types of non-protocol access to experimental treatments, including protocol exception, single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.

Study Results

Searches can be restricted to studies with or without results.

The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.

Recruitment Status

Also known as Enrollment Status.

Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.

If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.

Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.

Full list of all possible recruitment status values:

Open recruitment status values:

Recruiting,
Not yet recruiting, or
Available for expanded access.

Closed recruitment status values:

Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.

Values are color coded (as shown) in the search results.

Search Terms

Use this box to specify general search terms found anywhere in the trial record.

Multiple terms can be separated by an AND (all uppercase).

Examples:

type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study

Help for Searching clinical trials

Help Topics:

Basic Search
Advanced Search
Refine Search
Search Expressions

Basic Search:

On the Basic Search page, enter a word or word(s) that you want to use to find studies. These may include diseases, interventions, and/or locations.

Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,

Use of a Pacemaker Following a Heart Attack.

higher than the study,

Heart Defects and Transient Ischemic Attacks

A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.

Advanced Search:

Many searches are a single term and can be performed with a few words in the search box. But, sometimes you need more control. Click on the Advanced Search tab (if starting a new search) or Refine Search tab (if modifying an existing search) to show additional search fields.

The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.

Search Terms:

Performs a general search in all sections of the study record, including title, description, conditions, interventions, locations, etc. Terms in this field are searched the same as Basic Search.

Recruitment:

Limits search results to studies that are open or closed. New volunteers may be able to participate in open studies, but not closed studies.

Open recruitment status values:

Recruiting,
Not yet recruiting, or
Available for expanded access.

Closed recruitment status values:

Values are color coded (as shown) in the search results.

Study Results:

Limits search results based on whether the study has results or not:

All Studies,
Studies With Results, or
Studies Without Results

The inclusion of Study Results is a new feature of ClinicalTrials.gov. Only a few studies have results available.

Study Type:

Limits search results to any of the following study types:

Interventional,
Observational, or
Expanded Access

Conditions:

Performs a search on fields describing the diseases or conditions being studied.

Interventions:

Performs a search on fields listing the drugs or interventions being studied.

Outcomes Measures:

Performs a search on fields listing the outcome measures used to quantify study results.

Sponsor/Collaborators:

Performs a search on fields listing the sponsor and collaborators of a study.

When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.

Sponsor (Lead):

Performs a search on the sponsor field of a study.

It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.

When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.

Study IDs:

Performs a search on fields listing ID numbers.

Country/State:

Location Terms:

Finds studies in specific locations such as a city (Los Angeles) or facility (Mayo Clinic). Not all studies include this level of detail, but if they do, this will find them.

Gender:

Limits search results to those studies that accept female or male participants.

Age Group:

Limits search results to those studies that include at least one of the specified age ranges. More than one age group can be selected.

Phase:

Limits search results to studies that are labeled with at least one of the specified phases. More than one Phase can be selected.

Funded By:

Limits search results to studies that have at least one sponsor of the specified types. More than one sponsor type can be selected.

Safety Issue:

Limits search results to studies that have at least one outcome measure designated as a safety issue.

First Received:

Limits search results to studies that were received by clinical trials within a specified date range. The "From" or "To" field can be left blank.

Last Updated:

Limits search results to studies that were modified within a specified date range. The "From" or "To" field can be left blank.

Refine Search:

Searches display a list of studies found (List Results tab). If you are not content with the search results, click on the Refine Search tab at the top of the list to modify your search.

Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.

For example:

heart attack
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California

When you are done making changes, click Search to display the new results.

Search Expressions:

Use AND (all upper case) to find study records that contain all terms connected by AND.
For example:

prostate cancer AND radiation
heart disease AND stroke AND California

Use OR (all upper case) to find study records that contain either term connected by OR.
For example:

Aspirin OR ibuprofen
heart disease OR heart attack

Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:

Immunodeficiency NOT AIDS

Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:

prostate cancer AND NOT ( radiation OR homeopathic remedies )
( heart disease OR heart attack ) AND ( stroke OR clot )

Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,

Ear, Nose, and Throat Conditions

is the expression

( Ear OR Nose OR Throat ) AND Conditions

Fortunately, search will do a pretty good job of finding the right studies either way.

To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.

ICH GCP | Clinical Trials Registry

Clinical Trials: SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[BasicSearch] Leiomyosarcoma

Fill in any or all of the fields below.

Conditions

Rare Diseases

Drug
Interventions

Dietary
Supplements

Sponsor/
Collaborators

Locations

ICH GCP | Clinical Trials Registry

Clinical Trials: SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[BasicSearch] Leiomyosarcoma

Fill in any or all of the fields below.

Conditions

Rare Diseases

DrugInterventions

DietarySupplements

Sponsor/Collaborators

Locations

Drug
Interventions

Dietary
Supplements

Sponsor/
Collaborators